Fukutin-related protein is essential for mouse muscle, brain and eye development and mutation recapitulates the wide clinical spectrums of dystroglycanopathies.
Mutations in fukutin-related protein (FKRP) cause a common subset of muscular dystrophies characterized by aberrant glycosylation of alpha-dystroglycan (α-DG), collectively known as dystroglycanopathies. The clinical variations associated with FKRP mutations range from mild limb-girdle muscular dystrophy type 2I with predominantly muscle phenotypes to severe Walker-Warburg syndrome and muscle-eye-brain disease with striking structural brain and eye defects. In the present study, we have generated animal models and demonstrated that ablation of FKRP functions is embryonic lethal and that the homozygous-null embryos die before reaching E12.5. The homozygous knock-in mouse carrying the missense P448L mutation almost completely lacks functional glycosylation of α-DG in muscles and brain, validating the essential role of FKRP in the functional glycosylation of α-DG. However, the knock-in mouse survives and develops a wide range of structural abnormalities in the central nervous system, characteristics of neuronal migration defects. The brain and eye defects are highly reminiscent of the phenotypes seen in severe dystroglycanopathy patients. In addition, skeletal muscles develop progressive muscular dystrophy. Our results confirm that post-translational modifications of α-DG are essential for normal development of the brain and eyes. In addition, both the mutation itself and the levels of FKRP expression are equally critical for the survival of the animals. The exceptionally wide clinical spectrums recapitulated in the P448L mice also suggest the involvement of other factors in the disease progression. The mutant mouse represents a valuable model to further elucidate the functions of FKRP and develop therapies for FKRP-related muscular dystrophies.
Chan
Yiumo Michael
YM
McColl-Lockwood Laboratory for Muscular Dystrophy Research, Neuromuscular/ALS Center, Carolinas Medical Center, Charlotte, NC 28231, USA.
Keramaris-Vrantsis
Elizabeth
E
Lidov
Hart G
HG
Norton
James H
JH
Zinchenko
Natalia
N
Gruber
Helen E
HE
Thresher
Randy
R
Blake
Derek J
DJ
Ashar
Jignya
J
Rosenfeld
Jeffrey
J
Lu
Qi L
QL
D000818:Animals; D015139:Blotting, Southern; D015153:Blotting, Western; D001921:Brain / Q000196:embryology* / Q000502:physiology; D049030:Dystroglycans / Q000378:metabolism*; D005123:Eye / Q000196:embryology* / Q000378:metabolism; D005455:Fluorescent Antibody Technique; D017353:Gene Deletion; D015870:Gene Expression; D055879:Gene Knock-In Techniques; D006031:Glycosylation; D054081:Malformations of Cortical Development, Group II; D051379:Mice; D018345:Mice, Knockout; D023421:Models, Animal; D024510:Muscle Development; D018482:Muscle, Skeletal / Q000196:embryology* / Q000378:metabolism / Q000503:physiopathology; D009137:Muscular Dystrophy, Animal / Q000235:genetics / Q000378:metabolism; D020125:Mutation, Missense; D010430:Pentosyltransferases; D016133:Polymerase Chain Reaction; D011499:Protein Processing, Post-Translational; D011506:Proteins / Q000235:genetics / Q000378:metabolism*; D014166:Transferases
D011506:Proteins; D049030:Dystroglycans; D014166:Transferases; C499093:Fkrp protein, mouse; D010430:Pentosyltransferases